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Summary The tumour-suppressor gene p53encodes atranscription factorthat plays a critical role in the induction of G1 cell cycle arrest and
apoptosis after DNA damage. To clarify the role of the p53 gene and apoptosis in combined hyperthermia, chemotherapy and radiation
(hyperthermochemoradiotherapy, HCR therapy) for rectal cancer, we examined the histological response, rate of apoptosis, DNA
fragmentation and p53 status in tumours from 28 patients undergoing HCR therapy before surgery and from 22 patients who did not have
preoperative treatment. The therapeutic effect of HCR therapy was closely correlated with the rate of apoptosis; the correlation was
statistically significant, suggesting that this effect occurs through apoptosis. The incidence of p53 mutations in the treated group were as
follows: in tumours resistant to HCR therapy, four of seven (57.1%); intermediately sensitive, 7 of 13 (53.9%); or sensitive, three of eight
(37.5%), suggesting that the therapeutic effect and apoptosis rate were related to the p53 status of the tumours to some extent, but the
relation was not statistically significant. In the 22 control tumours (non-treated group), the apoptosis rate was 2.0 ± 1.1%, and there was no
significant difference in p53 status compared with the HCR group. Our study indicates that the pathological response to HCR therapy
correlates with the rate of apoptosis with statistical significance and that it induces the therapeutic effect more significantly in rectal cancer
cells with wild-type p53, although HCR therapy-induced apoptosis also occurs in some rectal cancers with mutated p53. Therefore, this
combination therapy can induce an additive or synergistic anti-tumour effect in rectal cancers with wild-type p53 as well as in those with
mutated p53through apoptosis, offering new therapeutic opportunities and a better prognosis.
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Mutations in thep53 tumour-suppressor gene are among the most
commonly identified genetic alterations in human cancers
(Hollstein, et al, 1991; Levine et al, 1991). In addition to its clear
role in tumour progression, recent evidence suggests that p53 is
highly involved in the cellular response to ionizing radiation
(Kastan et al, 1991; Kuerbitz et al, 1992). Levels of wild-typep53
increase after exposure to y-radiation because of a post-transla-
tional stabilization of the protein (Kastan et al, 1991). Cells
expressing wild-type p53 subsequently arrest the cell cycle at the
G,/S boundary after radiation, whereas cells lacking wild-type
p53, or containing a mutant form ofthe protein, continue to cycle
or arrest in G2 (Kuerbitz et al, 1992).
Much of the evidence for the involvement of p53 in radiation-
induced apoptosis is derived from work with cells from transgenic
animals, isogenic apart from the status ofthep53 gene. It has been
shown that thymocytes from p53-deficient mice are completely
resistant to the induction ofapoptosis aftery-radiation, but are still
sensitive to apoptosis induced by other cytotoxic agents (Lowe et
al, 1993). More recently, Merritt et al (1994) reported that cells of
the intestinal crypts of p53-null mice fail to undergo the rapid
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apoptotic cell death normally seen 3-4 h after the irradiation of
mice with the wild-type gene.
Despite the apparent critical nature of the p53-dependent
radiation-induced apoptotic response of haematopoietic cells and
certain tissues derived from transgenic animals, the role ofp53 in
the DNA damage response of solid tumour cells and cell lines
remains unclear. It has been found that extensive apoptosis occurs
with the induction of wild-type p53 in a p53-negative cell line
derived from human colon tumour (Shaw et al, 1992). In contrast,
Brachman et al (1993) found that the radiosensitivity of 24 cell
lines derived from head and neck cancers did notcorrelate with the
mutational status ofthep53 gene. Slichenmeyer et al (1993) found
no direct influence ofp53 gene status or G, checkpoint status on
the sensitivity of colorectal carcinoma cell lines to radiation-
induced cell death. Furthermore, they proposed that p53-depen-
dent apoptosis is a cell type-specific phenomenon and that the G2
checkpoint may be more important in determining radiosensitivity
(Slichenmeyer et al, 1993). Both hyperthermia and 5-fluorouracil
(5-FU) can induce apoptosis in cancer cells (Barry et al, 1990;
Takano et al, 1991; Shchepotin et al, 1994; Tomasovic et al, 1994),
but the role ofp53 in hyperthermia or 5-FU-induced apoptosis has
not been ascertained.
Various protocols for the radiation therapy ofrectal cancer have
been developed, and their clinical outcomes have been examined
carefully (Gerard et al, 1988; Neto et al, 1989; Pahlman et al,
1990; Stockholm Rectal Cancer Study Group, 1990). We have also
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Figure 1 (A) Extensive degenerative changes and fibrosis after HCR therapy in an ulcerated rectal cancer (HE staining, x 100). (B) Tunel staining nuclei
(apoptotic cells) scaftered in the same cancer (Tunel staining, x 200). (C) Fibrous changes in the centre of the main tumour. Pyknotic nuclei in fibrous tissue
(HE staining, x 200). (D) These pyknotic cells are Tunel positive, apoptotic cells (Tunel staining, x 200). (E) Many apoptotic cells are seen in the lumens of
cancerous tissue after HCR therapy (HE staining, x 200). The apoptotic cells have pyknotic or segmented nuclei, or apoptotic bodies. (F) These cells are
positive on Tunel staining (x200)
developed a preoperative combination therapy using irradiation,
intraluminal hyperthermia and 5-FU suppositories (HCR therapy)
for rectal cancer to prevent local recurrences and improve survival.
We have recently reported the results of a follow-up study,
showing that the preoperative treatment improves the prognosis of
these patients (Takahashi et al, 1982, 1993; Ichikawa et al, 1996)
but increases post-operative complications, such as anastomotic
leakage and pelvic infection (Takahashi et al, 1993). It is very
important to predict the sensitivity of rectal cancers to this preop-
erative therapy to prevent patients from receiving ineffective treat-
ments and to decrease the number ofpost-operative complications.
Considering these results, we therefore examined whether rectal
cancer cells show apoptosis after HCR therapy and whether the
effect ofHCR therapy is related to the p53 status ofthe tumour.
MATERIALS AND METHODS
Patients
From 1990 to 1995, 110 patients with advanced cancer of the
lower rectum admitted to the First Department ofSurgery at Kyoto
Prefectural University of Medicine were enrolled in this study.
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Figure 2 DNA fragmentation in rectal cancers after HCR therapy. Rectal cancers were treated with HCRtherapy. Biopsies were performed during the
HCR therapy. DNA was isolated from the biopsy specimens on both cancers (T) and surrounding mucosa (N) and wasanalysed using 1.5% agarose gel
electrophoresis. The marker is a Hindlll digest of x DNA. Cases 11 and 12 have wild-type p53, and cases 25 and 28 have mutantp53
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Figure 3 Relationship between the apoptosis rate and the grade of
response to HCR therapy. Positive cells by Tunel staining and grade of
response to HCR therapy were plotted in 28 cases (grade 1, seven cases;
grade 2,13 cases; grade 3; eight cases). As a control group, 22 non-treated
cases were plotted. *P < 0.05, **P < 0.01 compared with the controls (no
treatment cases)
Advanced rectal cancers were defined as those fixed to the
surrounding structures. All cancers were located in the rectum less
than 10 cm from the anal verge. The clinical evaluation of the
tumours consisted of physical examination, barium enema,
endoscopy, computerized tomography, magnetic resonance
imaging and endoscopic ultrasonography. Our study was directed
towards patients with American Joint Committee on Cancer Stage
T3 and T4 tumours that were surgically resectable. Patients with
distant metastases were excluded from this analysis. Patients were
randomly selected, and the treatment group consisted of 28
patients who underwent combination therapy with radiation,
intraluminal hyperthermia and 5-FU suppositories, and then had
surgery 7 days later. The control group included 22 patients who
underwent surgery without preoperative treatment.
Radiation
A 4-MeV linear accelerator or fiCo was used for the radiation
therapy. A bilateral irradiation technique through anteroposterior
portals was used to deliver the radiation to the area of the pelvis.
The ports were approximately 12 cm in diameter, surrounding the
carcinoma in the lower rectum. The target volume included the
whole dorsal part of the pelvic cavity from the anus up to the
promontorium. The inferior border was the bottom ofthe obturator
foramen, and the lateral border was 1 cm lateral to the bony
margin. Three times a week, 30 Gy was delivered in ten fractions.
Hyperthermia
To create hyperthermia in the rectal cancer, an intraluminal elec-
trode was developed that consisted of aradiofrequency emitter and
a cooling system. The radiofrequency system (Omron, HEH-500,
Kyoto, Japan) was used as described previously (Takahashi et al,
1982, 1993; Ichikawa et al, 1996).
5-Fluorouracil suppository
Studies ofcolorectal cancer in vivo and in vitro have suggested an
advantage when 5-FU is delivered in conjunction with radiation
therapy (Takahashi et al, 1982, 1993; Ichikawa et al, 1996).
Suppositories were made by dissolving 5-FU in a Witepsol
suppository base; each one contained 100 mg of5-FU.
Protocol
The protocols for the preoperative treatment were as reported
previously (Takahashi et al, 1982, 1993; Ichikawa et al, 1996). In
order to get ethical approval, doctors always explained the
protocol of HCR therapy and its possible complications, such as
proctitis, diarrhoea, nausea and general fatigue, just before HCR
therapy starts.
Pathological examination
In order to evaluate the histological changes induced by the
preoperative treatment, the surgical specimens were subjected to
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Table 1 p53gene mutations and chromosome 17 allelic losses in rectal
cancers treated with hyperthermochemoradiotherapy (HCR therapy)
Case Grade Codon Mutation Amino acid Number of
17p allele
1 1 Not detected 2
2 1 Not detected 2
3 3 Not detected 2
4 3 Not detected 2
5 1 Not detected 1
6 2 Not detected 2
7 2 Not detected 2
8 2 Not detected 2
9 2 Not detected 2
10 2 Not detected 2
11 2 Not detected 2
12 3 Not detected 2
13 3 Not detected 2
14 3 Not detected 2
15 1 159 GCC--GTC Ala-Val 2
16 2 175 CGC-+CAC Arg-1His 1
17 2 248 CGG-TGG Arg-Jrp 1
18 2 175 CGC-+CAC Arg-+His 1
19 2 248 CGG-*TGG Arg-*Trp 1
20 2 249 AGG-*AAG Arg-+Lys 1
21 3 166 TCA->TAA Ser-*Stop 1
22 3 275 1-bp Insertion Stop at 305 1
23 2 249 AGG->AAG Arg->Lys 1
24 3 166 TCA-TM Ser-+Stop 1
25 1 196 1-bp Deletion Stop at 246 1
26 1 159 GCC-*GTC Ala-Aal 1
27 2 275 1-bp Insertion Stop at 305 1
28 1 159 GCC-+GTC Ala-Xal 1
Case 24 Case 28
4-
N T N T
Figure 4 PCR-LOH analysis of a CA repeat at the p53 locus. Case
numbers are given at the top of each panel. T, tumour DNA; N, normal DNA.
Arrows indicate the allelic deletion in each case
pathological investigation. The histological changes observed
after the preoperative treatment were classified as follows: grade
0, no remarkable changes; grade 1, swelling of cells, enlarged
vesicles, pyknosis of nuclei and vacuolated cytoplasm (< 25%);
grade 2, cell nests consisting of markedly damaged cells, often
exhibiting a moth-eaten appearance and simplified granular struc-
tures; and grade 3, extensive degenerative changes and fibrosis
(< 75%), as previously described (Takahashi et al, 1982, 1993;
Ichikawa et al, 1996). Estimation ofhistological therapeutic effect
was performed in three orfourdifferent fields ofmicroscopic view
by clinical doctors and confirmed by the pathologists.
In situ end labelling (Tunel assay)
Tumour tissue from each patient was fixed and embedded in
paraffin, and sections 5 ,um thick were made according to routine
histological procedures. The in situ detection of apoptotic cells
was visualized according to the protocol of Wijsman et al (1993).
After rehydration with phosphate-buffered saline (PBS), the slides
were treated with terminal deoxynucleotidyl transferase (TdT) and
biotinylated dUTP for 1 h at 37°C. After washing three times with
PBS, peroxidase-conjugated avidin was applied, and the slides
were incubated for another 1 h at 370C, then incubated with DAB
for another 15 min. Finally, the slides were washed three times
with PBS and mounted with the mounting solution. The numberof
Tunel-positive cells was quantified in the light microscope and
was expressed as cells per surface area. Five randomly chosen
areas in each section were counted. Sections were also processed
for routine staining with haematoxylin and eosin (HE).
DNA extraction
For the analysis of p53 mutation, genomic DNA was extracted
fromparaffin-embedded tissues. First, 5-jim-thick sections on glass
slides were trimmed to remove as non-tumorous tissue as possible.
Then they were stripped and deparaffinized with xylene; the DNA
was extracted with PCRbuffercontaining Nonidet P-40 andTween
20 in a total volume of 90gl and was subjected to analysis ofp53
mutations. For the analysis ofDNA fragmentation on agarose gel,
fresh endoscopic biopsy samples were taken through colon fibre
examination during HCR therapy (day 5-10 after HCR therapy
starts), and the DNA was extracted from biopsy specimens in six
cases during HCR therapy, as described above.
PCR-SSCP (single-strand conformation polymorphism)
analysis
A setofPCRprimers flanking intron/exonjunctions4-8 ofthep53
gene were used based on the genomic sequence data by Bukhman
et al (1988). The nucleotide sequence of the primers were as
follows: 5'-CTCTTCCTGCAGTACTCCCCTGC-3'/5'-GCCCC-
AGCTGCTCACCATCGCTA-3' for exon 5, 5'-ACGACAGG-
GCTGGT TGCCCA-3'/5'-ACGACAGGGCTGGTTGCCCA-3'
for exon 6, 5'-GGCCTCATCTCGGGCCTGTG-3'/CAGTGT-
GCAGGGTGGCAAGT-3' for exon 7, 5'-CTGCCTCTTGCTT-
CTClTF-I 3'/5'-TCTCCTCCACCGCTTCTTGT-3' for exon 8
and 5'-GCCTClTTTCCTAGCACTGCCCAAC-3'/5'-CCCAAGA-
CTTAGTACCTGAAGGGTG-3' for exon 9. For each patient, the
five primerpairs were used in individual PCRs to amplify the p53-
coding sequences in genomic DNA from their tumour and from
normal mucosa. PCR was performed in a thermal cycler (Astek,
Fukuoka). The PCR reaction mixture (total 5 gl) contained
genomic DNA (50 ng), 1 mm of each deoxynucleotide triphos-
phate (dNTP), 1 FM 32P-end-labelled primer, 6.7 mm magnesium
chloride, 67 mM Tris-HCl (pH 8.8) and Taq polymerase (0.1 units,
Perkin Elmer Cetus, Norwalk, CT, USA). Thirty cycles consisting
of 60 s at 940C, 45-60 s at 60°C and 2 min at 720C were
performed. The reaction mixture was denatured at 80°C for 5 min
and was applied to a 6% polyacrylamide gel containing 45 mm
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Figure 5 PCR-SSCP analysis of the p53gene. The case number is shown
at the bottom of each lane. Lane N is control DNA. Cases 16 and 21 (exon 5)
and 17 (exon 7) show different mobilities
Tris-borate (pH 8.3) and 4 mm EDTA with or without 10%
glycerol. The gel was dried on filter paper and exposed to
autoradiographic film for 10 h at-80°C.
Direct sequencing
Samples with mobility shifts altered from the normal controls
were reamplifed without [y-32P]ATP and were purified using the
QlAquick-spin PCR purification kit (Qiagen, Chatsworth, CA,
USA). The PCR products were directly sequenced by the dideoxy
termination method using end-labelled sequencing primers
and the T7 Sequencing kit (Pharmacia LKB). Products were
electrophoresed on 8% polyarylamide gels containing 7 M urea.
Sequencing was performed at least twice on both sense and
antisense strands.
Allelic deletion analysis of 17p
To measure allelic deletions, PCR-LOH (loss of heterozygosity)
analysis using a microsatellite marker (TP53) (Jones et al, 1992)
within the p53 gene was performed (Baker et al, 1989). In a few
cases in which the probe was not informative, additional markers
(Gyapay et al, 1994) at chromosome 17p13 were analysed.
Statistical analysis
Associations between p53 mutations and the apoptosis rate were
evaluatedusing theX2 test. Thecriterion ofsignificance wasP<0.05.
RESULTS
Histopathological analysis
Massive fibrosis was observed in the resected specimens after
HCR therapy (Figure 1 A-D). Many apoptotic cells were found in
the fibrous tissue (Figure 1 A-D) as well as in the lumens of the
residual cancerous tissue (Figure 1 E and F). These apoptotic cells
had pyknotic or segmented nuclei, or apoptotic bodies. The
tumoricidal effects of the preoperative treatment were evaluated
microscopically in the resected specimens. Ofthe 28 patients who
had preoperative treatment, 21 cases (75%) demonstrated a histo-
logical anti-tumour effect (grade 1, seven cases; grade 2, 13 cases;
grade 3, eight cases). Such histological findings could not be
detected in cases without HCR therapy. Macroscopic tumour
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Figure 6 Direct genomic sequence analysis of the p53gene in the cases
shown in Figure 5. Mutated sequences were compared with a control DNA
(N) containing the normal p53 sequence. Case 16, codon 175 (G-*A) in
exon 5; case 21, codon 166 (C-*A) in exon 5; case 17, codon 248 (C-4T)
in exon 7
shrinkage did not always correlate with the histological effect
(data not shown), so only the histological examination was used to
estimate the anti-tumour effect in this study.
Tunel staining
Tunel-stained nuclei were scattered in the fibrous tissue and tubular
lumens of the residual cancer tissues (Figure 1 B, D and F).
Apoptosis was more easily observed in rectal cancers after treat-
ment with HCR therapy than in non-treated rectal cancers. An
intense Tunel signal was observed even in ordinary, non-pyknotic
nuclei oftumourcells, and occasionally in nuclear fragments corre-
sponding to apoptotic bodies. Necrotic foci of tumour cells and
nuclear ghosts showed faint, diffuse staining, implying non-specific
incorporation of nucleotides. Intense Tunel signal was observed in
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some ordinary non-pyknotic nuclei of tumour cells that on conven-
tional microscopic assessment of apoptosis would not be consid-
ered as undergoing apoptosis. No signals were detected in mitotic
cells or inflammatory cells in the tumour stroma.
DNA fragmentation on agarose gel
Genomic DNA was extracted from fresh endoscopic biopsy speci-
mens during HCR therapy in six cases. Typical DNA fragmenta-
tion was observed in case nos. 11 and 12 (wild-type p53) and case
nos. 25 and 28 (mutant p53) (Figure 2). Typical DNA fragmenta-
tion was not detected in another two cases after HCR therapy,
probably because ofcontamination ofnormal tissue or ineffective-
ness of HCR therapy.
Relation of therapeutic effect and apoptotic rate
The number ofapoptotic cells in the treated group increased with
increasing grade of therapeutic effect (*P < 0.05, **P < 0.01
compared with control, Figure 3) significantly. Therapeutic effect
correlated closely with the apoptotic rate, suggesting that this
combination therapy acts through the induction ofapoptosis.
Allelic deletion analysis of 17p
Chromosome 17p allelic loss was detected in 14 of 28 tumours
(50%) by dinucleotide-repeat polymorphisms (Table 1). Thirteen
of these 14 tumours also contained p53 gene mutations, but one
case with allelic loss did not have ap53 mutation in the remaining
allele (Table 1). Typical data is shown in Figure 4.
SSCP analysis and direct sequencing
Fourteen of 28 rectal cancers revealed mobility shifts in PCR-
SSCP analysis (Figure 5). Typical data is shown in Figure 5. The
position and type ofthep53 gene mutation was identifiedby direct
sequencing (Figure 6 and Table 1). The incidence of mutations in
the treated group were distributed as follows: (four of seven;
57.1%) grade 1 tumours (resistant tumour), 7 of 13 (53.9%) grade
2 tumours (intermediate tumour) and three of the eight (37.5%)
grade 3 tumours (sensitive tumour) (Table 1). The point mutations
correlated well with allelic loss at chromosome 17 in this study, as
otherinvestigators have described (Baker et al, 1989).
DISCUSSION
Various adjuvant therapies for rectal cancers have aimed to
prevent local recurrence, which is the most predominant prog-
nostic factor forpatients with advanced rectal cancer (Gerard et al,
1988; Neto et al, 1989; Pahlman et al, 1990; Stockholm Rectal
Cancer Study Group, 1990). Among various adjuvant therapies,
the most successful one is high-dose radiation or radiation
combined with other therapies. We have developed a novel pre-
operative therapy combining radiation, intraluminal hyperthermia
and 5-fluorouracil suppositories for advanced rectal cancer
(Takahashi et al, 1982, 1993; Ichikawa et al, 1996). This therapy
causes a striking tumoricidal effect and results in improved prog-
nosis (Takahashi et al, 1982, 1993; Ichikawa et al, 1996).
Sensitivity or resistance of tumour cells to ionizing radiation and
anti-cancer agents has substantial clinical consequences. There is
evidence that ionizing radiation and several chemotherapeutic
agents used to treat cancers act through the induction of apoptosis
(Kastan et al, 1991; Kuerbitz et al, 1992; Lee et al, 1993; Lowe et
al, 1993; Slichenmeyer et al, 1993; Kerr et al, 1994; Milas et al,
1994). 5-FU is one of the most commonly used chemotherapeutic
agents for the treatment of cancers and has been shown to produce
apoptosis in malignant cells (Barry et al, 1990; Shchpotin et al,
1994). Hyperthermia is also known to enhance the cytotoxic effect
of radiation (Nevaldine et al, 1994; Bisht et al, 1995). Many exper-
iments have shown the ability of mild hyperthermia to enhance
apoptosis in human and murine neoplastic cells (Takano et al,
1991; Tomasovic et al, 1994). Although the mechanism of apo-
ptosis induction by both hyperthermia and 5-FU has not yet been
clarified, it is highly possible that these different treatments - irra-
diation, 5-FU and hyperthermia - result in additive or synergistic
anti-tumour effects through apoptosis.
The p53 gene regulates apoptosis in some tissues (Lowe et al,
1993; Chiou et al, 1994; Dole et al, 1994) and has been shown to
directly affect the sensitivity of cancer cells to these agents (Kerr
et al, 1994; Milas et al, 1994). The p53-dependent induction of
apoptosis by y-radiation is of particular interest in the light of
observations that suggest thatp53 mutations increase resistance to
ionizing radiation (Lee et al, 1993) and that radiation-induced
apoptosis is abrogated in cells lacking wild-type p53 protein
(Clarke et al, 1993; Lowe et al, 1993, 1994; Merritt et al, 1994). In
contrast, the independence of radiosensitivity from p53 function
has also been reported in colon adenocarcinoma RKO cells
(Slichenmeyer et al, 1993) and head and neck cancer cell lines
(Brachman et al, 1993). These differences appear to be related to
the apoptotic potential of the cell lines used in these different
studies. These studies highlight the importance ofcellular context
to the evaluation of the biological properties of the p53 tumour
suppressor and its effector genes. In order to examine the mecha-
nism of action of our therapy, and to predict tumour sensitivity to
it, we examined the apoptosis rate and p53 status in rectal cancers
and examined the relationship between the therapeutic efficacy,
histological apoptosis rate and p53 status.
Many apoptotic cells (Tunel-positive cells) and massive fibrous
changes were observed in the surgically resected specimens after
HCR therapy (Figure 1). DNA electrophoresis revealed the typical
pattern of DNA fragmentation, a marker of apoptosis (Figure 2).
The therapeutic effect correlated with the apoptotic rate,
suggesting that this combination therapy acts through the induc-
tion of apoptosis (Figure 3). The p53 status of the tumours corre-
lated with therapeutic efficacy to some extent but the correlation
was not statistically significant. This may indicate that it is diffi-
cult to predict the sensitivity of rectal cancers to HCR therapy
using only p53 status. According to our preliminary experiments,
endoscopic biopsy specimens removed and examined during HCR
therapy show a high apoptosis rate in responsive tumours. This
rate was higher than in surgically resected specimens after HCR
therapy, probably because most apoptotic cells were destroyed and
disappeared during preoperative HCR therapy (data not shown);
this suggests that the apoptosis rate in endoscopic biopsy
specimens taken during HCR therapy may be useful in
determining the sensitivity of rectal cancers to HCR therapy.
Indeed, the use of Tunel assay for assessment of DNA damage
has been widely accepted as a reliable method of assessment of
DNA fragmentation and hence apoptosis. However, as DNA
damage may occur via mechanisms other than apoptosis, and as
apoptosis has been shown to occur in colorectal carcinoma
cell lines through both p53-dependent and p53-independent
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mechanisms (Shaw et al, 1992), it cannot be assumed that all
radiation-induced DNA fragmentation identifiable on Tunel assays
is due to apoptosis. Using Tunel assay, we should concentrate
on the relation of the therapeutic effect by HCR therapy and the
apoptotic rate.
p53 gene regulates many kinds of genes, for example the
apoptosis-related gene bax (Miyashita et al, 1995), the cell cycle
regulatorp21 (WAFl/CIP1) (Harper et al, 1993), the transcription
regulator GADD45 (Kastan et al, 1992), MDM2 (Momand et al,
1992), etc. These genes may be defective in rectal cancers and thus
may confuse the p53 status. Our study only looked at p53 status;
further studies are necessary to analyse the state of these other
genes and to determine whether the status ofp53 and its regulated
genes can be predictive for this treatment.
In summary, our study indicates that the pathological response
to HCR therapy correlates with the rate ofapoptosis with statistical
significance and that it induces the therapeutic effect more signifi-
cantly in rectal cancer cells with wild-type p53, although HCR
therapy-induced apoptosis also occurs in some rectal cancers with
mutatedp53. Therefore, this combination therapy can induce addi-
tive or synergistic anti-tumour effect in rectal cancers with wild-
type p53 as well as in those with mutated p53 through apoptosis,
offering new therapeutic opportunities and a better prognosis.
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HCR therapy, hyperthermochemoradiotherapy; 5-FU, 5-fluoro-
uracil; SSCP, single-strand conformation polymorphism
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